Roche Sues Pfizer to Block Breast-Cancer Biosimilar

Nov 21, 2017

Roche has sued to block Pfizer from selling a biosimilar of its breast-cancer drug Herceptin in the United States. In a complaint filed in federal court in Delaware, Roche's Genentech unit alleges that Pfizer’s proposed drug would infringe 40 patents.

Roche also is seeking compensation for lost sales if Pfizer launches its product before patents related to Herceptin expire.

According to Bloomberg, Herceptin earned $2.5 billion in U.S. sales in 2016 which accounted for 5 percent of Roche’s annual revenue.

Pfizer is seeking FDA approval of its version of Herceptin, called PF-05280014.

The case is Genentech v. Pfizer, 17-cv-1672, U.S. District Court, District of Delaware (Wilmington).

Read the Bloomberg report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments